Acrivon Shares Surge 33.8% Amid FDA Breakthrough Designation and CMO Appointment

Introduction

Acrivon Therapeutics, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts, with a research hub in Lund, Sweden. The company specializes in precision oncology and utilizes a proprietary proteomics-based patient selection platform (AP3) to develop targeted therapies for solid tumors. Its lead asset, ACR-368 (also known as Prexasertib), is currently in Phase 2 clinical development as a CHK1/2 inhibitor. Acrivon's internally developed pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor, alongside preclinical cell-cycle programs.

Corporate Structure and Leadership

With approximately 11 to 50 employees, Acrivon's executive team comprises individuals with substantial experience in both scientific and industry domains. Founder and CEO Peter Blume-Jensen, M.D., Ph.D., has extensive experience in precision-oncology research and invented the AP3 platform. Chief Development Officer Erick Gamelin, M.D., Ph.D., has overseen numerous oncology clinical trials. Co-Founder Kristina Masson, Ph.D., M.B.A., manages business operations and phosphoproteomic assay development. Jesper Olsen, Ph.D., serves as Head of Phosphoproteomics and is a professor of quantitative proteomics. Chief Operating Officer Eric Devroe, Ph.D., has founded multiple life sciences startups. Chief Financial Officer Adam D. Levy, Ph.D., M.B.A., has held senior roles in investor relations and corporate strategy at various biopharmaceutical companies. On August 13, 2025, Acrivon appointed Mansoor Raza Mirza, M.D., as Chief Medical Officer; Dr. Mirza has experience leading registrational trials in gynecologic oncology.

Precision oncology by National Cancer Institute

Recent Developments and News

• On August 13, 2025, Acrivon filed a Form 8-K (Acc-no: 0001193125-25-179834) reporting Dr. Mirza’s appointment and related compensatory arrangements. That same day, the company submitted its Form 10-Q for the quarter ending June 30, 2025 (Acc-no: 0000950170-25-108054), detailing research and development spending and cash reserves.
• On September 5, 2025, Acrivon filed a Form 8-K (Acc-no: 0001193125-25-197250) disclosing material updates related to its corporate governance practices.
• Also on September 5, the U.S. Food and Drug Administration granted Breakthrough Device Designation to Acrivon’s OncoSignature test for identifying endometrial cancer patients likely to respond to ACR-368.
• As of September 8, 2025, Acrivon’s common shares (NASDAQ: ACRV) closed at $1.78, reflecting an increase of 33.83% on a trading volume of 10,190,782 shares.

Financial and Strategic Analysis

Acrivon’s second-quarter Form 10-Q indicates that research and development expenses remain its primary expenditure, reflecting ongoing clinical trials for ACR-368 and ACR-2316. Current cash reserves support operations through late 2026. Revenue from collaboration or licensing agreements is limited at this stage. Strategically, Acrivon leverages its AP3 platform to develop predictive OncoSignature tests, aiming to enhance patient responder rates and expedite regulatory approvals. The in-licensed ACR-368 from Lilly shows durable single-agent activity, while internal programs are focused on expanding targets in the DNA damage response and cell-cycle regulation.

Market Position and Industry Context

The precision oncology sector is competitive, with genomic approaches sometimes limited in their predictive capabilities for specific targets. Acrivon’s proteomics-driven AP3 platform aims to enhance drug discovery by aligning mechanism-of-action with tumor biology. The global market for targeted therapies in endometrial, head and neck, and other solid tumors is significant, with Acrivon's focus on biomarkers potentially increasing response rates. The company's presence in both the Greater Boston and Scandinavian life sciences clusters offers access to clinical trial networks, biomarker discovery resources, and possible co-development partnerships.

tl;dr

On September 8, 2025, Acrivon’s shares increased by 33.83% to $1.78 (volume: 10.19 million). In early September, the company filed two Form 8-Ks—one detailing governance updates, and another announcing Dr. Mansoor Raza Mirza as Chief Medical Officer—and received FDA Breakthrough Device Designation for its ACR-368 OncoSignature test in endometrial cancer. The Q2 2025 10-Q confirms continued investment in R&D and projected cash reserves into late 2026. Upcoming milestones include Phase 2b data from ACR-368 and validation of the AP3 platform.